Results 1 to 11 of 11
Page 1 of 1
TypeTitleAuthor(s)YearViews
Telbivudine vs Lamivudine in HBeAg-Positive Patients with CHB: Two-Year Efficacy and Predictors of ResponseLai, CL; Gane, E; Hsu, CW; Chen, YC; Thongsawat, S; Wang, Y; Chen, Y; Naoumov, N; Han, SH; Hwang, SG; Lim, SG; Brown, NA2007116
 
Maximal Early Hbv Suppression In Nucleoside-treated Hepatitis B Patients Is Associated With Optimal Virologic And Clinical Efficacy At One YearLim, SG; Lai, CL; Thongsawat, S; Wang, Y; Chen, Y; Rasenack, J; Naoumov, N; Chao, G; Brown, N2006100
 
Effect of core promoter/precore mutation pattern and early virologic response on efficacy outcomes with telbivudine in HBeAg-negative chronic hepatitis BNaoumov, N; Lai, CL; Gane, E; Liaw, YF; Thongsawat, S; Wang, YM; Heathcote, EJ; Rasenack, J; Bzowej, N; Chao, G; Brown, N200698
 
Phase III comparison of telbivudine vs lamivudine in HBeAg-positive patients with chronic hepatitis B: Efficacy, safety, and predictors of response at 1 yearGane, E; Lai, CL; Liaw, YF; Thongsawat, S; Wang, YM; Cheng, Y; Heathcote, J; Rasenack, J; Bzowej, N; Naoumov, N; Chao, G; Fielman, B; Brown, N2006120
 
Role of regulatory T cells in natural immunity and sustained pharmacological control hepatitis B infection, The Liver Meeting of The American Association for the Study of LiverHui, CK; Zhang, H; Lee, PY; Marin, H; Yueng, YH; Leung, KW; Lu, L; Leung, N; Luk, JMC; Naoumov, N; Huang, F; Lau, G2006113
 
Optimal virologic and clinical efficacy at one year is associated with maximal early HBV suppression in nucleoside-treated hepatitis B patientsZeuzem, S; Lai, CL; Gane, E; Liaw, YF; Thongsawat, S; Wang, YM; Chen, Y; Heathcote, J; Rasenack, J; Bzowej, N; Naoumov, N; Chao, G; Fielman, B; Brown, N2006122
 
Telbivudine Globe Trial: Maximal Early HBV Suppression is Predictive of Optimal Two-year Efficacy in Nucleoside-treated Hepatitis B PatientsDiBisceglie A, A; Lai, CL; Gane, E; Chen, YC; Thongsawat, S; Wang, YM; Chen, YG; Heathcote, EJ; Zeuzem, S; Rasenack, J; Bzowej, N; Han, SH; Naoumov, N; Hwang, SG; Lim, SG; Chao, GC; Fielman, BA; Brown, NA; Study Group The GLOBE,2006178
 
Phase III Comparison of Telbivudine vs Lamivudine in Patients with Chronic Hepatitis B: Efficacy, Safety, and Predictors of Response at 1 YearBzowej, N; Lai, CL; Gane, E; Liaw, Y; Thongsawat, S; Wang, Y; Chen, Y; Heathcote, J; Rasenack, J; Naoumov, N; Chao, G; Fielman, B; Brown, N2006157
 
Two-year Results from the Globe Trial in Patients with Hepatitis B: Greater Clinical and Antiviral Efficacy for Telbivudine (LdT) vs LamivudineLai, CL; Gane, E; Hsu, CW; Thongsawat, S; Wang, YM; Chen, YG; Heathcote, EJ; Rasenack, J; Bzowej, N; Naoumov, N; Zeuzem, S; Di Bisceglie, A; Chao, GC; Barbara, A; Constance, F; Brown, NA; Study Group The GLOBE.,2006258
 
Telbivudine (LdT) vs. lmivudine for chronic Hepatitis B: First-year results from the international phase III GLOBE trialLai, CL; Gane, E; Liaw, YF; Thongsawat, S; Wang, YM; Chen, Y; Heathcote, J; Rasenack, J; Bzowej, N; Naoumov, N; Chao, G; Fielman, B; Brown, N; and the GLOBE Study Group, .2005156
 
Maximal early HBV suppression is predictive of optimal virologic and clinical efficacy in nucleoside-treated hepatitis B patients: scientific observations from a large multinational trial (the GLOBE study)Lai, CL; Gane, E; Liaw, YF; Thongsawat, S; Wang, YM; Chen, Y; Heathcote, J; Rasenack, J; Bzowej, N; Naoumov, N; Chao, G; Fielman, B; Brown, N; and the GLOBE Study Group, .2005134
 
Page 1 of 1
Export Records
Step 1: Select content and export format
  • Citation only
Step 2: Select export method
  • Download